The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 04, 2020

Filed:

Jun. 18, 2015
Applicants:

Chemotherapeutisches Forschungsinstitut Georg-speyer-haus, Frankfurt am Main, DE;

Drk Blutspendedienst Baden-wurttemberg-hessen Ggmbh, Frankfurt am Main, DE;

Inventors:

Winfried Wels, Frankfurt, DE;

Kurt Schonfeld, Langen, DE;

Torsten Tonn, Dresden, DE;

Manuel Grez, Heidelberg, DE;

Congcong Zhang, Frankfurt, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/32 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/32 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/2863 (2013.01); C12N 5/0646 (2013.01); C12N 15/86 (2013.01); A61K 35/17 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/70 (2013.01); C12N 2502/99 (2013.01); C12N 2740/16043 (2013.01);
Abstract

The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.


Find Patent Forward Citations

Loading…